Join us for an afternoon of industry-led discussions on innovation in rare disease diagnostics and treatments, along with the promising impact of these advancements on patient outcomes.

Register Now


BioCTEdge offers you substantial savings on the products and services you use the most.

Explore Offers


A diverse community of innovators committed to the growth and sustainability of our life science community.

Join Now

Stay Informed

Keep up-to-date on the latest news, events, BioCT happenings, and more.

Sign Me Up


Your source for today’s talent, job opportunities and career development.

Career Center

BioCT is the voice of Connecticut’s life science industry.

BioCT’s mission is to catalyze and market the growth of Connecticut’s life sciences industry; fostering and promoting the state as nationally recognized for innovation and improving patient lives.

Upcoming Events


The Jackson Laboratory: Women X Women

Leading JAX scientists will discuss infertility caused by endometriosis and cancer treatments, and the impact of genetic diversity on our ability to fight disease. This...

Academic R&D Investment
Bioscience Patent
VC Funding Per Capita
Most Educated Workforce in the US
Biological/Biomedical Advanced Degrees
NIH Funding Per Capita
Most Diverse State in New England
Most Innovative State

BioCT is grateful for the support of our partners & sponsors.

Exclusive member benefits

We’ve partnered with MassBio to bring you an even-bigger purchasing program featuring the supplier discounts their members enjoy.
Save big on everything you need, from travel to office products to lab supplies and more.

Click for Discounts


The Roundup – February 29, 2024

View this email in your browser February 29, 2024 Member News Arvinas moves ahead with 2 new drugs BIO: What policy biotech should be watching this election...

The Roundup – February 22, 2024

View this email in your browser February 22, 2024 Member News Ancera: Monitoring system can help producers manage coccidiosis Arvinas Announces first-in-human dosing of ARV-102, an...

The Roundup – February 15, 2024

View this email in your browser February 15, 2024 Member News A new class of cancer drugs is coming: Pfizer & Arvinas‘ hot pursuit of protein degrader technology...